Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Morpho-functional evaluation of corneal neovascularization disease after subconjunctival bevacizumab (pilot)
2007-003253-88Phase 2Completed
- Sponsor
- Policlinico Gemelli
- Start
- Jul 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in corneal neovascularization (CNV), sponsored by Policlinico Gemelli. Primary endpoint: Reduction of corneal neovascularization. Started Jul 2009; status: completed.
02
Drugs
bevacizumab
03
Conditions
corneal neovascularization (CNV)
Beyond the preview
Go deeper on 2007-003253-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003253-88.